RA Capital Management is a Boston-based investment firm specializing in healthcare, life sciences, and planetary health. It pursues evidence-based, science-led investing through its internal TechAtlas research engine and supports portfolio companies via its Raven healthcare incubator. The firm engages across stages from seed funding to IPOs and follow-on financings, focusing on drugs, medical devices, diagnostics, and other biomedical innovations, with a regional emphasis on the United States and Europe.

OrbiMed is a global healthcare investment firm based in New York, founded in 1989. It manages capital across public and private markets, including private equity, venture and growth investments, and private credit, with structured debt and royalty arrangements to support owners of intellectual property and diagnostics. The firm focuses on biopharmaceuticals, life sciences, medical devices, diagnostics, health IT, and healthcare services, investing from startups to multinational companies. With a worldwide team and offices in multiple regions, OrbiMed provides financing and strategic resources to advance therapies and healthcare innovations, aiming to improve patient outcomes across global markets.

Invus is a long-standing private investment firm founded in 1985 that partners with entrepreneurs and owner-managers to drive transformational growth. It emphasizes long-term alignment of incentives and provides capital and strategic guidance to help companies scale and innovate. With offices in New York, London, Paris and Hong Kong, Invus manages a substantial evergreen capital base that affords flexible engagement across private equity, co-investments, and related opportunities. The firm backs market-leading management teams across sectors such as consumer products, technology, life sciences, software, agtech, industrials and services, often taking both lead and co-investment roles. Through affiliated advisory and investment entities, Invus combines financial backing with strategic counsel to support enduring value creation over time.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, founded in 2016. The firm focuses on the healthcare sector, investing in biotechnology companies across the United States and serving as an investment adviser to support the development of transformative therapeutics. By combining scientists, clinicians, drug developers, and business leaders with extensive experience, Samsara BioCapital aims to accelerate the next generation of therapies through collaborative partnerships and strategic capital. The firm operates as a principal investor and provides guidance to entrepreneurs seeking to turn their ideas into successful biotech ventures.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. It operates a multi-strategy platform that encompasses growth equity, private equity including buyouts, venture capital, and public equity, and it has invested in over 290 public and private companies. The firm supports a broad range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets. Its multidisciplinary team includes physicians, scientists, entrepreneurs, operating executives, and industry experts, who collaborate across strategies to build high-quality companies in the United States and China.

The European Innovation Council is a European Union institution that funds and accelerates deep-tech innovation across Europe. It provides substantial support to startups, researchers, and technology transfer activities through programs such as the EIC Accelerator, EIC Fund, and EIC Prizes, and offers business acceleration services to help scale and globally expand ventures. The council is described as a major investor, providing about €6.5 billion in funding, and it co-invests with private investors in early-stage startups with ESG impacts. Established in 2018 and headquartered in Brussels, it focuses on breakthrough innovations in deep technology, including dual-use and defence-relevant technologies, and engages with innovation ecosystems through events, reports, and information hubs. The organization is oriented toward advancing European competitiveness by nurturing high-potential tech ventures from inception through scaleup.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotechnology, life sciences, and related technology sectors. It backs early-stage to growth-stage companies across human health, planetary health, and bioeconomy, including drug development and MedTech. The firm manages roughly €5 billion across about 11 funds and operates with a global footprint through offices in the Netherlands, Germany, and the United States. It integrates ESG principles into portfolio companies and pursues societal impact alongside financial returns.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

New Enterprise Associates is a global venture capital firm founded in 1977 and based in Menlo Park, California. It provides capital and operational support to companies across development stages, from seed to IPO, with a focus on technology and healthcare sectors. The firm collaborates with founders to address technical challenges, offering domain expertise to assist product development and market expansion. NEA invests across the United States, Asia and Brazil, and its portfolio includes software, consumer technology, medical devices, life sciences, healthcare information technology, and energy technology companies. With a long track record of helping entrepreneurs achieve growth, NEA emphasizes enduring partnerships and strategic guidance alongside funding to build transformational businesses through multiple stages of a company lifecycle.

TCG Crossover is a science-driven healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve patients' lives. It invests in both private and public companies led by entrepreneurs developing better treatment options, with teams in Palo Alto and New York City. The firm leverages scientific expertise to identify and back breakthrough pharmaceutical therapies and health technology opportunities, aiming to accelerate innovation in the pharmaceutical sector and to help management teams translate discovery into patient benefit.

ARCH Venture Partners is a venture capital firm founded in 1986 and based in Chicago, Illinois, with additional operations in Seattle. The firm focuses on science-based companies, prioritizing life sciences and related technologies, and aims to translate academic and national lab innovations into commercially viable products. ARCH emphasizes a true partnership approach, providing capital alongside strategic guidance, expertise, and a broad professional network to founders. It has supported numerous companies across early to growth stages and is known for backing translational efforts that bring breakthrough discoveries to market, leveraging collaborations with researchers and entrepreneurs to accelerate development of disruptive technologies on a national and international scale.

Logos Capital is a biotechnology investment firm based in San Francisco, founded in 2019. It uses a disciplined, data-driven approach that combines in-house analytics with scientific and clinical expertise to identify transformative therapeutics. The firm conducts rigorous fundamental research across clinical, regulatory, operational, and commercial dimensions of drug development, leveraging a proprietary data science platform called Logos Analytics to assess clinical success probability. With an emphasis on risk management, Logos Capital aims to deliver long-term, uncorrelated returns through thorough due diligence and a holistic view of asset value.

Deep Track Capital is a venture capital firm headquartered in Greenwich, Connecticut. Founded in 2020, it concentrates on the life sciences and biotechnology sectors, investing in public and pre-IPO biotechnology companies. The firm emphasizes a hands-on partnership approach, providing capital, scientific expertise, and an extensive network to management teams. It seeks to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, aiming to accelerate the development and commercialization of innovative biotech ventures.

Deerfield Management is a healthcare-focused investment firm that advances human health by investing in both public and private healthcare companies and by supporting research and development initiatives. The firm targets a broad range of healthcare sectors, including biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, and healthcare services. It seeks to create value through long-term capital deployment, collaboration with strategic partners, and its internal efforts to foster scientific research and drug discovery. In addition to investment activity, Deerfield operates philanthropic initiatives through the Deerfield Foundation that fund education, expanded healthcare access, and health-outcomes improvement.

Sofinnova Partners is an independent venture capital firm based in Paris, founded in 1972, specializing in life sciences. It invests across seed to growth stages in biopharmaceuticals, biotechnology, medical devices, digital health, and related areas, including corporate spin-offs and select turnaround opportunities. The firm acts as a lead or cornerstone investor and frequently takes board seats, working closely with entrepreneurs from formation through exit to build companies with market leadership. Sofinnova emphasizes hands-on support, strategic guidance, and long-term relationships, and operates with multiple investment strategies to back early-stage accelerators and later-stage ventures. Its portfolio aims to improve health and well-being and sustain innovation across healthcare and sustainability sectors.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco with offices in Canada, the United States, and Europe. It invests across the healthcare sector, including biotechnology, pharmaceuticals, and medical devices, at multiple stages, with an emphasis on the discovery and development of novel therapeutics. The firm combines financial backing with scientific and operational support, leveraging in-house scientists and collaborations with academic institutions to help portfolio companies advance from discovery to development and commercialization. Versant has a track record of portfolio companies achieving acquisitions or public offerings, reflecting its focus on translating scientific innovation into clinically meaningful products.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It focuses on seed through early-stage investments and selected later-stage opportunities in life sciences and information technology across the United States and Europe. In life sciences, it backs clinical-stage pharmaceutical products, biotechnology, biopharmaceuticals, therapeutic drugs and medical technology platforms addressing unmet medical needs, with initial investments typically in the low millions and total commitments in the tens of millions; the firm often requires a board seat when leading or co-leading early rounds. In information technology, it supports product-oriented IT, enterprise software, service-provider software and telecommunications infrastructure across development stages. Sofinnova collaborates with entrepreneurs to secure initial funding, build teams, win customers and navigate acquisitions and IPOs, leveraging domain expertise to help portfolio companies scale globally. It does not invest in healthcare services, diagnostics, nutraceuticals or tool-kit ventures.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on investing in life sciences and related technologies. The firm targets opportunities in healthcare and biotech, including digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, with activity across North America and Western Europe. Omega Funds acts as a registered investment adviser, supporting early-stage and growth companies as they develop therapeutic and digital health solutions.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in early-stage investments in biotechnology and life sciences, with additional focus on technology companies. It partners with life science entrepreneurs to translate scientific discoveries into medicines and related diagnostics, often leading seed or Series A rounds and providing strategic guidance and board involvement. Founded in 1980, Atlas Venture has organized multiple funds and operates with dedicated Life Sciences and Technology teams to manage portfolio companies across the United States and Europe. Its portfolio emphasizes biopharmaceuticals, therapeutics, and medical technologies, along with software and data-driven technologies that support life science commercialization.

SR One is the corporate venture capital arm of GlaxoSmithKline. Founded in 1985 and based in Redwood City, California, it operates as a transatlantic biotechnology venture capital firm focused on translating innovative scientific discoveries into new medicines. It invests globally in life sciences companies across biotechnology, healthcare, medical devices, and information technology, employing a back-and-build approach that prioritizes robust fundamentals and clear development plans. With a presence on the US West Coast and in London, SR One provides portfolio companies with geographic reach, regional expertise, and real-time business support to accelerate the progression of science toward new treatments.

EcoR1 Capital is a venture capital firm based in San Francisco that invests in early-stage biotechnology companies developing innovative therapeutics. It applies a scientific approach, leveraging advances in molecular biology to identify promising ventures and support their pursuit of new medicines. The firm emphasizes partnering with entrepreneurs dedicated to therapeutic innovation and provides strategic and scientific guidance to help translate breakthrough discoveries into treatments for patients.

SOSV is a global venture capital firm focused on early-stage deep-tech and cross-border software companies, investing primarily from pre-seed through growth stages. It accelerates product development, regulatory progress, fundraising, and commercial strategy by providing founders access to purpose-built labs, engineering spaces, and a broad physical and virtual infrastructure across multiple locations. The firm's program-driven approach combines selective funding with hands-on support, mentorship, and a wide network of co-investors and partners to help portfolio companies scale. SOSV operates a suite of specialized facilities for deep-tech founders, including incubation programs that connect startups with customers, researchers, and investors, and it emphasizes long-term relationships through ongoing operational and strategic assistance. While active globally, it maintains strong ties to Asia-focused cross-border markets and supports a diverse portfolio spanning bio-tech, hardware, robotics, software, and related fields.

HBM Healthcare Investments is a Swiss investment company focused on healthcare, managing a globally diversified portfolio of private and public healthcare companies. Based in Switzerland and established in 2001, the company targets opportunities across human medicine, biotechnology, diagnostics, and medical technology, seeking to benefit from demographic growth, medical advances, rising prosperity, and the increasing need for new therapies. The business emphasizes exposure to the rapidly expanding global healthcare market through a mix of private holdings, public investments, and related assets, aiming to generate value and long-term growth for investors.

Commodore Capital is a New York-based venture capital firm focused on biopharmaceuticals. Founded in 2019, the firm concentrates on early-stage companies developing innovative therapies, with emphasis on genetic medicines and cellular therapies, during a period of rapid scientific advancement translating into clinical breakthroughs. It aims to be a supportive partner to smaller biopharmaceutical companies as they develop and deliver new medicines to patients globally.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in San Diego, California, it invests in both public and private biotechnology and life sciences companies across the drug development lifecycle, with a focus on precision medicine and oncology. The firm emphasizes rigorous, science-driven due diligence spanning scientific, clinical, regulatory, and commercial aspects to identify promising opportunities. It supports portfolio companies through independent investment decisions grounded in thorough research and seeks to back innovative assets and companies across private and public markets.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across the lifecycle of a company, from inception to development and expansion. It supports therapeutic and medical innovations in Europe by investing across early-stage to growth opportunities and by collaborating with leading academic research institutions and hospitals. The firm manages multiple funds, including Kurma Biofund I, II and III, the Kurma Diagnostics fund, and the Kurma Growth Opportunities Fund, and invests in healthcare, life sciences, digital health, and related technology sectors.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including drug discovery and healthcare technology. It backs companies across the development spectrum, from early discovery to commercialization, with a long-term approach aimed at creating multiple product opportunities rather than quick exits. The firm manages substantial capital and operates an ecosystem of funds such as Platform, Opportunity, Labs-Soleil, and Crossover to support portfolio companies. Founded in 2007, The Column Group has generated significant returns for its partners and invested in numerous biotech ventures, including 55 companies with 18 exits. The organization emphasizes rigorous science, mentorship, and access to networks to advance portfolio programs in cancer, neurological, and other therapeutic areas.

BioVenture is a Suzhou-based investment firm focused on early and growth-stage healthcare in the life sciences sector with a global outlook. Since its founding in 2013, it has invested in more than 200 life sciences companies across four core areas—new drug discovery, medical devices, diagnostics and precision medicine, and healthcare services—with 19 portfolio companies having gone public on HKEX or the STAR Market. The firm operates four platforms—pharma/biotech, devices, diagnostics and precision medicine, and medical services—leveraging extensive industry resources and partnerships to drive portfolio growth. It emphasizes post-investment management and value-added services, supported by a team of experienced investment professionals and senior scientific advisors. Through a platform network anchored in bioBAY at Suzhou Industrial Park, BioVenture is regularly recognized among China’s top healthcare venture capital firms and remains active in funding innovative medical and pharmaceutical ventures.

Casdin Capital is a New York-based venture capital and investment firm focused on the life sciences and healthcare sectors. Founded in 2012 by Eli Casdin, the firm backs companies across genomic research, molecular medicine, precision medicine, diagnostics, synthetic biology, oncology, digital health, and related technologies. It pursues a data-driven, long-term investment approach and seeks to form strong partnerships with portfolio companies to advance scientific innovation and improve patient outcomes. The firm engages with ventures at various stages, from early- to late-stage private companies, emphasizing opportunities at the intersection of biology and technology. Through its activity in life sciences and healthcare, Casdin Capital positions itself as a partner to founders pursuing breakthroughs in genomics, molecular medicine, and AI-enabled healthcare platforms.

Mission BioCapital is a life science venture capital firm that backs early-stage biotechnology and life sciences companies. With leadership that has a long history of founding and supporting dozens of startups, the firm operates from Cambridge, Massachusetts and San Francisco, California, leveraging a network of researchers and venture capital partners. It provides mentorship, collaboration, and hands-on support from concept through clinical trials, including access to shared laboratory space through its Platinum Program, which offers up to $500,000 in funding, a lab bench, and related services for promising startups. The firm focuses on accelerating scientific solutions and actively participates in portfolio company growth across therapeutic areas, backing companies through multiple funds.

Pontifax is a Herzliya-based private equity and venture capital firm focused on healthcare and life sciences. Founded in 2004, it invests across incubation to late-stage growth in areas including biopharma, medical devices, diagnostics, bioinformatics, and related sectors such as agricultural productivity, sustainability, and supply-chain tech. The firm pursues global opportunities with a particular emphasis on Israel and often takes minority stakes while providing strategic guidance, board representation, and deep industry networks to portfolio companies. Pontifax aims to back transformative technologies across development stages and geographies, helping startups move from idea to market.

MPM BioImpact is a venture capital firm focused on building and funding biotechnology companies to transform patient outcomes by developing innovative medicines. Based in Boston, the firm brings more than three decades of experience in translating scientific research into clinical impact and pursues opportunities across the biotechnology, healthcare, and life sciences sectors in the United States. It supports the full drug development process, from discovery through clinical proof of concept and regulatory milestones, with emphasis on areas such as oncology, immunology, neuroscience, and mental health. MPM BioImpact combines deep scientific expertise with strategic leadership to help portfolio companies navigate development challenges and accelerate patient-ready therapies. The firm has backed notable companies across its focus areas, leveraging hands-on guidance and collaboration to translate science into meaningful medical advances.

venBio Partners is a California-based venture capital firm focused on life sciences, investing in U.S. companies from early to late stages with an emphasis on novel therapeutics and drug discovery. The firm typically leads investments and builds syndicates, applying hands-on involvement to optimize development programs and strategic positioning. venBio emphasizes strong intellectual property, robust chemistry, manufacturing and controls, and comprehensive clinical development plans, including trial design, endpoints, powering, and regulatory considerations, to help portfolio companies meet potential partner and acquisition criteria from the outset. It seeks to improve patient care through its portfolio and aims to form lasting relationships with leaders in the life sciences sector, with offices in San Francisco and Seattle and global operations.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and first-round investments in technology and healthcare, with a broad remit across information technology, life sciences, media, energy, and emerging tech. The firm backs early- and growth-stage companies and has supported a number of notable portfolio companies, including Apple Computer, Intel, Illumina, Gilead Sciences, Endeca, Imperva, DoubleClick, Athenahealth, Centocor, Check Point Software, Nest, SlideShare, and Tudou. Venrock emphasizes partnering with entrepreneurs to build enduring companies and leverages its long history in technology and healthcare to help founders navigate growth, strategy, and complex markets.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 that provides seed- and early-stage capital to life sciences companies. The firm focuses on biopharmaceuticals, medical devices and instruments, digital health, and related health technologies, with an emphasis on early-stage private therapeutics and other life science ventures in the United States. It supports early rounds such as Series A and collaborates with academics, researchers, and entrepreneurs to advance proof-of-concept data and development programs. The company operates primarily from its San Francisco headquarters and maintains a presence in Boston, reflecting its national investment scope. It runs initiatives to discover and incubate breakthrough science through internal programs designed to accelerate translational work and product progress. Overall, 5AM Ventures aims to help promising healthcare and life science companies grow from concept to commercialization.

Lumira Ventures is a North American life sciences and healthcare venture capital firm with offices in Toronto, Montreal, Vancouver and Boston. It partners with entrepreneurial management teams to build innovative biotherapeutic, medical device, digital health and consumer health companies that address meaningful unmet needs. Since its inception, Lumira Ventures has invested in more than 100 healthcare companies and currently supports a portfolio of over 30 active investees across Canada and the United States. The firm focuses on early- to late-stage venture opportunities, providing financings, active board participation and help with access to additional funding, strategic partnerships and market channels to maximize the value of technology pipelines. The organization aims to drive transformational impact in patient care through its portfolio companies.

Third Rock Ventures is a Boston-based venture capital firm founded in 2007 that invests in life sciences and healthcare companies, including biotechnology, medical devices, diagnostics, therapeutics, and related information technology. The firm targets early-stage and growth opportunities, frequently leads rounds, and takes an active role in portfolio companies, often pursuing strategic collaborations with larger pharmaceutical and biotechnology partners to advance medicines and technologies. Its focus spans oncology, autoimmune diseases, genetic disorders, and other therapeutic areas with the aim of improving patient outcomes through innovative drug development and diagnostics.

Ally Bridge Group is a global life sciences investment firm founded in 2013 and headquartered in New York, with a presence in Asia and Europe. It focuses on healthcare, biotechnology, medical technology, and related disruptive platforms, investing across private equity, venture, growth, and select public equities. The firm targets companies at early to development stages and aims to support transformative advances in drugs, diagnostics, medical devices, and related technologies. It emphasizes scientific and commercial conviction, proprietary research, and board-level engagement to help portfolio companies advance patient care, reduce costs, and expand global reach. Through its network, Ally Bridge Group collaborates with innovators to bridge research and commercialization, seeking meaningful impact beyond capital.

Pivotal bioVenture Partners is a San Francisco–based venture capital firm focused on life sciences, including therapeutics, medical devices, diagnostics, and related platforms. Founded around 2017, the firm invests in privately held companies across North America and Europe, and maintains a China presence to support opportunities in Greater China. The team combines venture investing experience with drug discovery, development, and company-building expertise to back early- through late-stage ventures and to provide strategic guidance. The firm operates globally with offices in San Francisco, Shanghai, and Hong Kong, and is affiliated with Nan Fung Life Sciences, reflecting a broader platform that supports transformative therapies and healthcare innovations.

Catalio Capital Management is a New York-based investment firm focused on the full lifecycle of innovative healthcare companies across private, public, and credit markets. It pursues a multi-asset approach, including venture capital, structured opportunities, public equities, and co-investments, to back life sciences and technology-driven companies at various stages and capital structures. As of 2025, Catalio manages about $2 billion in assets and employs over 40 professionals across New York, Washington, DC, and London, supported by a network of roughly 45 venture partners who provide proprietary deal flow and domain expertise. The firm concentrates investments in drugs, AI-enabled technologies, and devices, and seeks strategic exits alongside ongoing value creation. Catalio emphasizes scientific leadership and collaboration with world-class scientists-entrepreneurs, aiming to translate breakthrough research into scalable healthcare solutions.

Abingworth is an international life sciences investment firm founded in 1973 with offices in London, Boston, and Menlo Park. It collaborates with life sciences entrepreneurs to develop ideas into products that significantly impact health, investing across all development stages from startups to publicly traded companies and across all life sciences sectors. Supported by a team of 27 professionals, the firm has over $1 billion under management and has invested in 142 life science companies, with 60 IPOs and 40 mergers and acquisitions completed.

Aisling Capital is a New York-based private investment firm focused on healthcare and life sciences. Founded in 2000, it invests in mid-market and growth-stage companies across the United States and Western Europe, seeking to back companies developing innovative therapies, diagnostics, and related technologies. The firm aims to support global healthcare leaders by providing capital to advance development and commercialization of new products. With extensive healthcare industry experience, Aisling Capital has built a track record of investments in areas such as neuroscience and biotechnology and has been involved in notable acquisitions and partnerships within the sector.

Medicxi is a life sciences-focused venture capital firm headquartered in London, with additional offices in Geneva and Jersey. Founded in 2016 by the former Index Ventures life sciences team, the firm builds on more than two decades of experience in drug discovery and therapeutics development. Medicxi backs biotechnology and healthcare companies across Europe from seed to late-stage rounds, including drug development, biotechnology platforms, and related technology-enabled therapies. The firm emphasizes hands-on support and strategic value creation to advance promising therapies from discovery to clinical development, leveraging its sector expertise and network to accelerate progress for unmet medical needs.

Khosla Ventures is a California-based venture capital firm founded in 2004 that backs technology-driven startups across multiple sectors, including artificial intelligence, healthcare, sustainability, digital health, and consumer technology. The firm provides capital and strategic guidance to companies at early and growth stages, with an emphasis on disruptive technologies and world-changing businesses. It operates a range of funds, including seed and later-stage vehicles, and maintains a broad investment thesis that covers AI, climate tech, energy efficiency, and other high-potential areas, primarily focused in the United States. The firm is known for working closely with entrepreneurs to build long-lasting companies.

Longitude Capital is a venture growth investment firm focused on life sciences, including biotechnology, medical technology, and health solutions. Established in 2006 and based in Menlo Park, California, it targets clinically de-risked assets across private and public life-science companies. The firm seeks to build balanced portfolios of clinical-stage and commercial-stage assets with attractive risk-adjusted returns within three to five years. It relies on a broad industry network and thematic research to identify opportunities in emerging therapeutic areas, and employs a range of investment structures such as traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open-market purchases, royalties, and other equity-linked instruments. The firm emphasizes strategic partnerships to support portfolio companies through fundraising and liquidity events.

U.S. Venture Partners is a venture capital firm based in Menlo Park, California, founded in 1981. It specializes in early-stage investments in information technology and healthcare, including enterprise software, IT security, consumer internet, mobile, e-commerce, and IT-enabled healthcare services. The firm backs entrepreneurs across the United States and Israel, aiming to turn ideas into world-changing companies and to create economic value and jobs over its multi-decade history. The team comprises former entrepreneurs, technologists, corporate executives, financial professionals, and industry experts who work with portfolio companies to scale growth in software, healthcare, and related sectors.

Alumni Ventures is a venture capital firm that provides accredited investors access to venture-stage and late-stage private market investments. It offers funds, syndicates, investing clubs, and co-investment opportunities with established venture capital firms, and it provides venture investing education through AV Academy along with resources for startup founders.

IMM Private Equity is an independent private equity firm based in Seoul, South Korea, specializing in significant minority investments and middle-market buyouts. Established in 2006, the firm concentrates on Korea-related opportunities and typically pursues active roles in portfolio companies to drive value. Its investment focus spans growth capital, turnaround, mezzanine, and buyout transactions across sectors such as manufacturing, information technology, healthcare and biotechnology, and consumer-related industries, with additional cross-border opportunities in Asia. The firm benefits from a longstanding network of institutional investors and a disciplined investment approach that emphasizes rigorous analysis and value creation through operational improvements. IMM Private Equity operates within the IMM group, a holding and capital management platform that includes affiliated private equity and credit activities, leveraging integrated relationships and experience across Korea’s evolving private capital market.

Ysios Capital is a Spanish independent venture capital firm focused on life sciences and human healthcare. Founded in 2008 and based in Donostia-San Sebastián, it manages roughly €350 million to €400 million across dedicated funds and backs early- and mid-stage companies developing novel therapies, diagnostics, medical devices, and platform technologies across Europe and North America. The firm supports development through scientific and entrepreneurial guidance, often taking board seats, and seeks to finance product development and breakthrough innovations with the aim of helping patients and delivering growth for portfolio companies. Exits are typically pursued through mergers, acquisitions, or public offerings, reflecting a disciplined, long-term approach to value creation in the life sciences and healthcare sectors.

Longwood Fund is a Boston-based life science venture investment firm focused on identifying and supporting innovative technologies and the teams developing them to advance patient care. It funds and guides early-stage science through clinical development and commercialization, concentrating on healthcare, pharmaceutical, and biotechnology sectors. The firm leverages a broad network of industry experts to advise and accelerate the growth of its portfolio companies from discovery to market. Since its founding in 2010, Longwood has demonstrated a track record of translating scientific breakthroughs into tangible treatments, with several portfolio companies bringing products to market and multiple therapies advancing in late-stage development. The organization continues to seek opportunities in promising life science ventures and provides strategic support to teams throughout the development journey.